Notable Wednesday Option Activity: ZVRA, KOD, PEN
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts has been traded thus far today, a contract volume which is representative of appr...
Nasdaq News: Markets
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...
PR Newswire
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 3, 2026 Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the...
PR Newswire
Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates
Ono Pharmaceutical Co. (OPHLF) delivered earnings and revenue surprises of +60.00% and +5.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire...
PR Newswire
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease...
Business Wire
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics PR Newswire NEW YORK, July 28, 2026 Zevra shareholders...
PR Newswire
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (Zevra or the Company) (NASDAQ: ZVRA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...
Business Wire
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) PR Newswire NEW YORK, July 27...
PR Newswire